Destiny-PanTumor02 is a global, open-label, multicentric, phase II trial evaluating the efficacy and safety of T-Dxd in patients with previously treated HER2-expressing solid tumours [14] (locally advanced, unresectable, or metastatic biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, or other solid cancers, excluding breast, colorectal, gastric, and non-small-cell lung cancers). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.